Short Term
Mean Reversion
Very Weak
Trend
Neutral
Event
Neutral
Halo Model
MQV
Very Strong
GARP
Very Strong
MQV Small
Neutral
Momentum
Price
Very Strong
Earnings
Very Strong
Growth
Earnings
Strong
Dividends
Very Strong
Quality
Capital Efficiency
Very Strong
Balance Sheet
Weak
Website
N/ATelephone
61.13.0097.4621
Address
Level 10 324 Queen Street Brisbane, Queensland (QLD) 4000
Description
Microba Life Sciences Ltd. engages in the provision of microbiome testing, supplements and analysis services as well as developing new pathology services, therapeutics, and diagnostics based on the human gut microbiome. It operates through the Testing Services and Supplements and Research and Development segments. The company was founded by Gene Tyson and Philip Hugenholtz on January 31, 2017 and is headquartered in Brisbane, Australia.
Market Cap
PE
EV/EBITDA
DIV Yield
Franking
Ex Dividend Date (est.)
52 weeks range
Low 0.08 - 0.32
Trade Value (12mth)
AU$11,668.00
1 week
-4.6%
1 month
-36.15%
YTD
-57.44%
1 year
-51.18%
All time high
0.42
EPS 3 yr Growth
87.60%
EBITDA Margin
-197.90%
Operating Cashflow
-$16m
Free Cash Flow Return
-38.70%
ROIC
-49.60%
Interest Coverage
-345.60
Quick Ratio
2.40
Shares on Issue (Fully Dilluted)
448m
HALO Sector
Healthcare
Next Company Report Date
27-Aug-25
Ex Dividend Date (est.)
N/A
Next Dividend Pay Date (est.)
N/A
Reporting Currency
AUD
Short Sell (% of issue)
0.05
Date | Announcements |
---|---|
02 July 25 |
Ceasing to be a substantial holder
×
Ceasing to be a substantial holder |
27 June 25 |
Application for quotation of securities - MAP
×
Application for quotation of securities - MAP |
27 June 25 |
Disclosure Document - Prospectus
×
Disclosure Document - Prospectus |
27 June 25 |
Letter to SPP Eligible Shareholders
×
Letter to SPP Eligible Shareholders |
27 June 25 |
Cleansing Notice
×
Cleansing Notice |
23 June 25 |
Suspension from Quotation
×
Suspension from Quotation |
23 June 25 |
Microba secures $14.5 million to drive clinical adoption
×
Microba secures $14.5 million to drive clinical adoption |
23 June 25 |
Proposed issue of securities - MAP
×
Proposed issue of securities - MAP |
23 June 25 |
Strategic Investment & Equity Raise Presentation
×
Strategic Investment & Equity Raise Presentation |
23 June 25 |
Proposed issue of securities - MAP
×
Proposed issue of securities - MAP |
23 June 25 |
Proposed issue of securities - MAP
×
Proposed issue of securities - MAP |
23 June 25 |
Proposed issue of securities - MAP
×
Proposed issue of securities - MAP |
23 June 25 |
Reinstatement to Quotation
×
Reinstatement to Quotation |
19 June 25 |
Trading Halt
×
Trading Halt |
21 May 25 |
MetaPanel Pathogen Study Delivers Breakthrough Results
×
MetaPanel Pathogen Study Delivers Breakthrough Results |
14 May 25 |
Landmark GI Study Results from over 4,600 patients
×
Landmark GI Study Results from over 4,600 patients |
12 May 25 |
Notification of cessation of securities - MAP
×
Notification of cessation of securities - MAP |
30 April 25 |
Q3 FY25 Quarterly Activities Report & Appendix 4C
×
Q3 FY25 Quarterly Activities Report & Appendix 4C |
30 April 25 |
Q3 FY25 Quarterly Investor Presentation & Webinar
×
Q3 FY25 Quarterly Investor Presentation & Webinar |
28 April 25 |
Details of Q3 FY25 Quarterly Report, Appendix 4C & Webinar
×
Details of Q3 FY25 Quarterly Report, Appendix 4C & Webinar |
02 April 25 |
HealthInvest 2025 Investor Conference Presentation
×
HealthInvest 2025 Investor Conference Presentation |
20 March 25 |
Diagnostics Growth & Metrics Webinar - Part B
×
Diagnostics Growth & Metrics Webinar - Part B |
20 March 25 |
Webinar Presentation - Diagnostics Deep Dive - Part A
×
Webinar Presentation - Diagnostics Deep Dive - Part A |
04 March 25 |
Investor Webinar & Newsletter
×
Investor Webinar & Newsletter |
26 February 25 |
Appendix 4D & FY25 Interim Report
×
Appendix 4D & FY25 Interim Report |
Load More
Load Less
Historical data
Forecast data
Load More
Load Less
Historical data
Forecast data
Load More
Load Less
Historical data
Forecast data
Load More
Load Less
Percent of Issue
Value ($M)
Prior Change
7 Day Change
1 Month Change
3 Month Change
Access data on short interest, stock performance, and potential short-selling candidates across various markets to make informed decisions and optimize your trading strategies.
Unlock true investor intelligence
Research, trade and manage global markets from one place with HALO Global. It’s trading - the way you want it.
Get the latest insights and hot tips delivered right to your inbox
HALO Technologies Pty Ltd ABN 54 623 830 866 is a Corporate Authorised Representative No 1261916 of Macrovue Pty Ltd ABN 98 600 022 679 AFSL 484264. Macrovue Pty Ltd is a wholly owned subsidiary of HALO Technologies Pty Ltd.